Latent cytokines for targeted therapy of inflammatory disorders
| Autor: | Anne Rigby, Sandrine Vessillier, David Baker, Gill Adams, Lorna Layward, Lisa Mullen, Alex Annenkov, Gayatri Mittal, Michelle Sclanders, Yuti Chernajovsky, David Gould |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_treatment
Pharmaceutical Science Inflammation Peptide Matrix metalloproteinase Proinflammatory cytokine Targeted therapy Drug Delivery Systems Transforming Growth Factor beta Animals Humans Medicine Protein Precursors chemistry.chemical_classification biology business.industry Cytokine chemistry Immunology biology.protein PEGylation Cytokines Antibody medicine.symptom Peptides business |
| Zdroj: | Expert Opinion on Drug Delivery. 11:101-110 |
| ISSN: | 1744-7593 1742-5247 |
| Popis: | The use of cytokines as therapeutic agents is important, given their potent biological effects. However, this very potency, coupled with the pleiotropic nature and short half-life of these molecules, has limited their therapeutic use. Strategies to increase the half-life and to decrease toxicity are necessary to allow effective treatment with these molecules.A number of strategies are used to overcome the natural limitations of cytokines, including PEGylation, encapsulation in liposomes, fusion to targeting peptides or antibodies and latent cytokines. Latent cytokines are engineered using the latency-associated peptide of transforming growth factor-β to produce therapeutic cytokines/peptides that are released only at the site of disease by cleavage with disease-induced matrix metalloproteinases. The principles underlying the latent cytokine technology are described and are compared to other methods of cytokine delivery. The potential of this technology for developing novel therapeutic strategies for the treatment of diseases with an inflammatory-mediated component is discussed.Methods of therapeutic cytokine delivery are addressed. The latent cytokine technology holds significant advantages over other methods of drug delivery by providing simultaneously increased half-life and localised drug delivery without systemic effects. Cytokines that failed clinical trials should be reassessed using this delivery system. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|